Lyra Therapeutics (LYRA)

• Market cap: $5.7M
• 1 day: -5.98%
• 5 days: 3.72%
• 1 month: -47.58%
• 3 months: -54.62%
• 6 months: -62.84%
• Year to date: -59.95%
• 1 year: -98.40%
• 5 years: -99.53%
• 10 years: -99.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Employees: 30

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

8.62% less ownership

Funds ownership: 49.7% [Q3] → 41.08% (-8.62%) [Q4]

11% less funds holding

Funds holding: 62 [Q3] → 55 (-7) [Q4]

34% less capital invested

Capital invested by funds: $8.36M [Q3] → $5.55M (-$2.81M) [Q4]

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $2 2,212% upside
• Avg. target: $2 2,212% upside
• High target: $2 2,212% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 16 / 68 met price target

2,212% upside $2

Neutral Reiterated

14 Mar 2025